RP-7214 is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Brequinar is under clinical development by Clear Creek Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

It is for people with acute myeloid leukaemia aged 55 years and older. This study is looking at how the COVID-19 vaccines affect the immune system of people with cancer and chronic illnesses. This ...

The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but these individuals have a high mortality risk, according to a study ...